Biotech Investors Eye the Explosive PD1 Oncology Opportunity (MRK, OTLC, BMY, RHHBY, BGNE, GMAB)

The PD-1 blocker market has exploded into place as one of the most important and promising major biopharma oncology markets yet to appear. Immuno-oncology drugs that block the checkpoint PD-1 have been some of the most successful stories in the industry over recent years, launching blockbuster drugs like Opdivo and Keytruda – central assets from […]

QBioMed (QBIO): Counter Punching Glaucoma with Powerful Combinations

May 15, 2019 – WallstreetPR.com, the leading agency and financial media network dedicated to covering the biotech industry, announces the publication of an article covering QBioMed (QBIO) who is counter punching glaucoma with powerful combinations combating one of the leading causes of vision loss worldwide and the leading cause of irreversible blindness worldwide. Glaucoma is […]

EastGate (ETBI) Lands $38 Million in Milestone Payments with European Pharmaceutical Consortium

EastGate Biotech (ETBI) announced that it signed a non-dilutive licensing deal with a European consortium of several medium sized drug makers that gives them rights to market the oral insulin mouth rinse to the European market.  The consortium will have a 15 year exclusive license with a 10% royalty payable to ETBI. Nico Innovagroup mentioned […]